C-Reactive Protein Not Ideal in Testing for Heart Disease
February 19, 2010 – For women concerned about heart disease, routine testing of high-sensitivity C-reactive protein (hs-CRP) is controversial, said Thomas Behrenbeck, M.D., Ph.D., a Mayo Clinic cardiologist, in an interview in the February issue of Mayo Clinic Women’s HealthSource.
CRP is a marker for inflammation within the body and has been promoted as a screening test for coronary artery disease. Inflammation can play an important role in atherosclerosis. Interest in hs-CRP originated when studies found that patients with unstable angina or chest pain had high levels of this marker. Researchers found that hs-CRP could be used to predict who would go on to have a heart attack. But other studies have shown that hs-CRP isn’t a predictor of heart attack risk in people without symptoms of heart disease.
“If hs-CRP is elevated, it is worrisome because it tells you there is inflammation in the body,” Dr. Behrenbeck said. “But it doesn’t mean the inflammation is related to coronary artery disease.” Inflammation can be a response to any type of injury or infection. People who have rheumatoid arthritis have very high levels of hs-CRP. Elevated levels also can be caused by a bruise or a minor surgical procedure such as a tooth extraction.
For now, Dr. Behrenheck said there is no good role for hs-CRP screening in patients without symptoms of coronary artery disease. “We’ve been unable to determine if knowing your hs-CRP level is helpful beyond all of the other traditional risk factors – such as high blood pressure, diabetes, smoking and high cholesterol,” he said.
He advises women to continue to focus on the traditional risk factors. Controlling these risk factors is especially important post-menopause, when a woman’s risk of coronary heart disease increases.
Mayo Clinic Women’s HealthSource is published monthly to help women enjoy healthier, more productive lives. Revenue from subscriptions is used to support medical research at Mayo Clinic.
For more information: www.bookstore.mayoclinic.com
More like this
- Intermediate Risk Patients Benefit From Statin Therapy
- Study Analysis Shows CRESTOR Reduces Risk of Blood Clots in Veins
- Siemens Highlights High Sensitivity C-Reactive Protein Test
- FDA Committee Looks Favorably on Giving Cholesterol Drug to Healthy People
- Atherotech Adds New Cardiometabolic Tests For AMI, Stroke, Kidney Disease